ArticleBiochemistry and biophysics reports2025
Effects of alpha-ketoisocaproate in oxidative stress-induced C2C12 myotubes via inhibition of p38 MAPK and ERK1/2.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Broccoli-Derived Peptides and Leucine in Combination Ameliorate D-Galactose-Induced Sarcopenia in Mice.Nutrients · 2026Article
- Oxidative Stress in Neurodegenerative Disorders: A Key Driver in Impairing Skeletal Muscle Health.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is an age-related muscle atrophy characterized by decreased muscle mass and function. However, potential treatments to alleviate sarcopenia remain limited. In this study, we investigated the effects of α-ketoisocaproate (KIC) on C2C12 differentiation and reactive oxygen species (ROS)-induced atrophy in C2C12 myotubes. We demonstrated that KIC upregulates the expression of myogenic differentiation factors, including myoblast determination protein 1 (MyoD) and myogenin (MyoG), during C2C12 differentiation. Additionally, KIC enhanced the expression of myosin heavy chain (MHC) isoforms MHC1, MHC2b, and MHC2x in C2C12 myotubes. KIC suppressed the decreased MyoG expression and the increase in the muscle atrophy-related factor, muscle atrophy F-box (MAFbx), in ROS-induced C2C12 myotubes. In addition, it restored the reduced expression of MHC and the diameter of C2C12 myotubes. We showed that KIC alleviated muscle atrophy by inhibiting mitogen-activated protein kinase (MAPK) signaling pathways, such as p38 MAPK and extracellular signal-regulated kinase 1/2 (ERK1/2). These findings suggest that KIC may serve as a potential therapeutic agent for ameliorating sarcopenia by inhibiting MAPK signaling in ROS-induced skeletal muscle cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.